• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Tiny Diabetes Tech in the Pipeline

Slideshow

A tooth-mounted sensor, a glucose monitor built into a smartphone case, plus 3 more new “gee whiz” devices that could transform diabetes care.

slideshow image

Diabetes Tech in the Pipeline. A miniaturized tooth sensor that can measure sugar, salt, and alcohol intake and a glucose monitor built into a smartphone case are just 2 in a wide range of new diabetes technologies in development. Our diabetes technology reviewer picked the 5 devices in this slide show based on their potential for improving diabetes care and enhancing patients’ quality of life.

Please note: The images used to illustrate this slideshow reflect the concepts and ideas behind the technology, not the actual technology or device being described. Links to additional information are provided in each caption. 
 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Related Content
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Grace Halsey
July 9th 2025
Article

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

Sydney Jennings
June 26th 2025
Article

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

Sydney Jennings
June 23rd 2025
Article

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes / image credit ADA Julio Rosenstock, MD

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults With Type 2 Diabetes

Grace Halsey
June 23rd 2025
Article

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

© 2025 MJH Life Sciences

All rights reserved.